Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that finasteride effectively inhibits the enzymatic activity of human steroid 5 alpha reductase type II in newly established CHO cell lines.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

In this study, Tolterodine Tartrate significantly improved symptoms of overactive bladder and showed fewer adverse reactions compared to the control group treatment.

Propranolol affects heart rate and renin levels in minoxidil-treated patients.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This study presents the crystal structure of human SRD5A2 with finasteride and reveals insights into its enzyme catalysis and inhibition mechanisms, which may inform drug development.

This study identified eight isoflavone derivatives as potential nonsteroidal inhibitors of rat 5α-reductase using a pharmacophore model in virtual screening.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

In this study, 5α-reductase inhibitors were found to have no significant impact on preventing tumorigenesis or progression in in vitro models of urothelial cancer.

This study found that dual 5α-reductase inhibition in rats led to decreased sperm motility and altered morphology, resulting in subfertility.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

This study found that black cohosh extract BNO 1055 reduced testosterone-induced prostate and seminal vesicle growth in rats, suggesting it may contain potent 5α-reductase inhibitors useful for prostate cancer prevention.

In this study, 17β-estradiol increased VEGF production in differentiated THP-1 cells, while dihydrotestosterone counteracted this effect by modulating adenylate cyclase activity.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This study found that minoxidil increased plasma renin activity in patients with hypertension through both an adrenergic mechanism related to heart rate changes and a secondary mechanism unrelated to propranolol.

This article outlines the synthesis of spiro[cyclohexane‐1,2′‐[2 H ]indene] derivatives similar to known steroid 5α‐reductase inhibitors, but it does not report experimental findings.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

This study examined finasteride, a 5-alpha-reductase inhibitor, for treating a Tourette’s syndrome patient unresponsive to traditional therapy, noting its limited side effects.

Dutasteride reduces DHT more effectively than finasteride.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

A new compound may effectively inhibit the enzyme linked to BPH and hair loss.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This study found that the phytosterols β-sitosterol, stigmasterol, and campesterol have low-to-negligible inhibitory activity against steroidal 5α-reductase type 2 compared to the synthetic inhibitor dutasteride, with β-sitosterol showing the highest activity among the tested phytosterols.

This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.